

APPENDIX IV

STATUTORY AND GENERAL INFORMATION

FURTHER INFORMATION ABOUT OUR COMPANY

1. Incorporation of Our Company

Our Company was established as a limited liability company in the PRC on April 25, 2016 and was converted into a joint stock company with limited liability on September 23, 2025 under the laws of the PRC. As of the Latest Practicable Date, the registered share capital of our Company was RMB92,717,838 divided into 92,717,838 Unlisted Shares with a nominal value of RMB1.00 each.

Our Company has established a place of business in Hong Kong at 19/F, Golden Centre, 188 Des Voeux Road Central, Hong Kong and has registered as a non-Hong Kong company in Hong Kong under Part 16 of the Companies Ordinance. Mr. POON Ping Yeung (潘秉揚), our joint company secretary, has been appointed as our authorized representative for the acceptance of service of process in Hong Kong whose correspondence address is the same as our place of business in Hong Kong.

2. Changes in Share Capital of Our Company

On April 25, 2016, our Company was established as a limited liability company with a registered capital of RMB500,000. On September 23, 2025, our Company was converted into a joint stock company with limited liability, and our registered capital was RMB92,061,897 divided into 92,061,897 Shares with a nominal value of RMB1.00 each. As of the date of this document, our registered capital was RMB92,717,838 divided into 92,717,838 Unlisted Shares with a nominal value of RMB1.00 each.

Upon completion of the [REDACTED] (assuming the [REDACTED] is not exercised), our issued share capital will increase to RMB[REDACTED], made up of [REDACTED] H Shares fully paid up or credited as fully paid up, representing [REDACTED]% of our issued share capital.

Save as disclosed in “History, Development and Corporate Structure” in this document, there has been no alteration in our share capital within two years immediately preceding the date of this document.

3. Changes in the Share Capital of Our Subsidiaries

Our subsidiaries as of the Latest Practicable Date are set out in note 1 to the Accountants’ Report.

APPENDIX IV

STATUTORY AND GENERAL INFORMATION

Guangdong Synyi Intelligent Technology Co., Ltd.

On June 28, 2024, Guangdong Synyi Intelligent Technology Co., Ltd. (廣東森億智能科技有限公司) was established with registered capital of RMB5 million.

Save as disclosed above, there has been no alteration in the share capital of our subsidiaries within two years immediately preceding the date of this document.

4. Resolutions of the Shareholders

Pursuant to a general meeting of our Company held on September 24, 2025, the following resolutions, among others, were passed by our Shareholders:

- (a) the issue by our Company of H Shares of a nominal value of RMB1.00 each and that such H Shares be [REDACTED] on the [REDACTED];
- (b) that the number of H Shares to be [REDACTED] shall not be more than [REDACTED]% of the total issued share capital of our Company as enlarged by the [REDACTED] (before the exercise of the [REDACTED]), and the grant to the [REDACTED] (or their representatives) of the [REDACTED] of not more than [REDACTED]% of the number of H Shares [REDACTED] pursuant to the [REDACTED];
- (c) subject to the completion of the [REDACTED], the adoption of the Articles of Association which shall become effective on the [REDACTED], and the authorization to the Board to amend the Articles of Association in accordance with the requirements of the relevant laws and regulations and the Listing Rules; and
- (d) authorization of our Board to handle all relevant matters relating to, among other things, the [REDACTED] and [REDACTED] of the H Shares.

APPENDIX IV

STATUTORY AND GENERAL INFORMATION

FURTHER INFORMATION ABOUT THE BUSINESS OF OUR COMPANY

1. Summary of Material Contract



We [have] entered into the following contract (not being a contract entered into in the ordinary course of business) within the two years immediately preceding the date of this document that is or may be material:

(a) the [REDACTED].

2. Intellectual Property Rights

Trademarks

As of the Latest Practicable Date, we have registered the following trademarks, which we consider to be material to our business:

No.	Owner	Registration No.	Place of Registration	Trademark	Class	Validity Period
1. . .	Our Company	63671771	PRC		42	From August 21, 2023 to August 20, 2033
2. . .	Our Company	54933309	PRC		9	From December 28, 2021 to December 27, 2031
3. . .	Our Company	54900914	PRC		9	From October 14, 2021 to October 13, 2031
4. . .	Our Company	51116446	PRC		9	From August 21, 2021 to August 20, 2031
5. . .	Our Company	51103032	PRC		42	From February 14, 2022 to February 13, 2032

APPENDIX IV STATUTORY AND GENERAL INFORMATION

No.	Owner	Registration No.	Place of Registration	Trademark	Class	Validity Period
6. . .	Our Company	38511035	PRC	SYNYI	5	From January 28, 2020 to January 27, 2030
7. . .	Our Company	38499702	PRC	SYNYI	10	From January 28, 2020 to January 27, 2030
8. . .	Our Company	38499529	PRC	SYNYI·AI	42	From January 28, 2020 to January 27, 2030
9. . .	Our Company	38499527	PRC	SYNYI	42	From January 28, 2020 to January 27, 2030
10. .	Our Company	38499499	PRC	SYNYI·AI	5	From January 28, 2020 to January 27, 2030
11. .	Our Company	38495849	PRC	SYNYI·AI	9	From January 21, 2020 to January 20, 2030
12. .	Our Company	38491252	PRC	SYNYI·AI	44	From January 21, 2020 to January 20, 2030
13. .	Our Company	38491249	PRC	SYNYI	44	From January 21, 2020 to January 20, 2030
14. .	Our Company	38491247	PRC	森亿	44	From January 21, 2020 to January 20, 2030
15. .	Our Company	38491180	PRC	森亿	5	From April 14, 2020 to April 13, 2030

APPENDIX IV STATUTORY AND GENERAL INFORMATION

No.	Owner	Registration No.	Place of Registration	Trademark	Class	Validity Period
16.	Our Company	38486462	PRC	SYNYI·AI	10	From January 21, 2020 to January 20, 2030
17.	Our Company	38484948	PRC	SYNYI	9	From January 21, 2020 to January 20, 2030
18.	Yilianwang	31214163	PRC	YILINKN	42	From April 28, 2019 to April 27, 2029
19.	Yilianwang	31217555	PRC	YILINKN	9	From April 28, 2019 to April 27, 2029

Patents

The table below sets forth our core invention patents.

No.	Patent Title	Application Number	Application Date	Authorization Date
1 . .	Integrated Modeling System Based on Machine Learning	ZL202011256749.4	2020-11-11	2021-10-15
2 . .	Multi-Model Management Method, System, Medium, and Server	ZL202010840382.4	2020-8-20	2020-11-20
3 . .	Training Dataset Generation Method, System, Device, and Medium Based on Annotated Text	ZL202010622293.2	2020-6-30	2021-8-27
4 . .	Analysis Method, System, Medium, and Device Based on User Data Modeling	ZL202011250084.6	2020-11-11	2021-7-9
5 . .	Database Query Statement Generation Method, System, and Terminal Based on Knowledge Graph	ZL2024103467508	2024-3-26	2024-7-30
6 . .	Surgery Scheduling System, Method, Storage Medium, and Terminal Based on Deep Learning	ZL202010692852.7	2020-7-17	2023-11-7
7 . .	Medical Core Term Knowledge Base Construction Method, Device, Medium, and Terminal	ZL2024104445050	2024-4-15	2024-9-3

APPENDIX IV STATUTORY AND GENERAL INFORMATION

No.	Patent Title	Application Number	Application Date	Authorization Date
8 . .	Knowledge Graph Construction Method, System, and Terminal Based on Clinical Business Data	ZL2024103004633	2024-3-15	2025-5-6
9 . .	Medical Name Normalization Method, Device, Storage Medium, and Terminal	ZL202010633727.9	2020-7-2	2021-7-13
10 . .	Clinical Information Rule Extraction Method, Storage Medium, and Device Based on Data-Driven Approach	ZL202111500068.2	2021-12-9	2024-2-2
11 . .	Cross-Language Fusion Computing Method, System, and Terminal Based on Omega Engine	ZL202111033503.5	2021-9-3	2023-5-9
12 . .	Medical Expression Editing Method, Device, Equipment, and Medium Based on SVG Elements	ZL202010568165.4	2020-6-19	2021-4-27
13 . .	Source Data Acquisition Method, System, and Terminal for Rule Engine	ZL2024102935712	2024-3-14	2025-5-6
14 . .	Medical Data Analysis Method, System, Medium, and Device	ZL202011250091.6	2020-11-11	2024-7-9
15 . .	Heterogeneous Data Source Data Integration Method, System, and Terminal	ZL202010566643.8	2020-6-19	2021-7-30
16 . .	Database Variable Production Method, System, Computer Equipment, and Storage Medium	ZL202010608464.6	2020-6-29	2021-11-16
17 . .	Hospital Data Analysis Method, Hospital Data Analysis Platform, Equipment, and Medium	ZL202010566697.4	2020-6-19	2021-8-27
18 . .	Big Data Processing Method, Device, Equipment, and Storage Medium Based on Sensitive Data	ZL201910876650.5	2019-9-17	2020-8-7
19 . .	Funnel-Type Medical Data Insight System, Method, Medium, Program Product, and Terminal	ZL202411276465.X	2024-9-12	2025-2-14
20 . .	Unified Query Method, System, Medium, Product, and Terminal for Multi-Source Data Assets	ZL202410566296.7	2024-5-9	2024-9-3
21 . .	Multi-Dimensional Search and Viewing Method, System, and Terminal for Medical Data	ZL202410586644.7	2024-5-13	2024-10-1
22 . .	Medical Data Item Asset Sensitivity Identification Method, System, Terminal, and Medium	ZL2024104891085	2024-4-23	2024-9-3
23 . .	Patient Record Matching Method, Storage Medium, and Device Based on Patient Master Index	ZL202111500071.4	2021-12-9	2025-2-18
24 . .	Visual Regular Expression Rule Matching Method, System, and Terminal	ZL202111032140.3	2021-9-3	2024-2-20

APPENDIX IV STATUTORY AND GENERAL INFORMATION

No.	Patent Title	Application Number	Application Date	Authorization Date
25 . .	Visual Dataset Construction Management Method, System, Medium, and Device	ZL202010756092.1	2020-7-31	2020-11-13
26 . .	Medical Text Rapid Entry Method, System, Terminal, and Editor	ZL202311360931.8	2023-10-20	2024-2-6
27 . .	Document Format Data Loading and Rendering Method, Terminal, Medium, and Web Editor	ZL202310713413.3	2023-6-16	2023-11-7
28 . .	One-Click Deployment Method, System, and Storage Medium Suitable for Offline Environments	ZL202210041286.2	2022-1-14	2025-7-4
29 . .	PDF Repair Method, Storage Medium, and Device Based on Non-Standard Mapped Fonts	ZL202210036736.9	2022-1-13	2024-3-1
30 . .	Role-Based Multi-Tenant Organization Structure Management System, Method, Device, and Medium	ZL202010723048.0	2020-7-24	2023-11-7
31 . .	Scenario-Based Virtual Department Business Permission Control Method, System, and Terminal	ZL202010599331.7	2020-6-28	2024-12-10
32 . .	Data Permission Control Method, System, Terminal, and Storage Medium	ZL202010582484.0	2020-6-23	2023-11-7
33 . .	Method, Device, Equipment, and Medium for Dynamically Displaying or Hiding Headers and Footers	ZL202010568138.7	2020-6-19	2021-4-27
34 . .	Medical Big Data File Export Method, System and Terminal Based on Memory-Mapped Files	ZL202411352551.4	2024-9-26	2025-12-16

Note:

* Sort by importance to our operation.

Copyrights

As of the Latest Practicable Date, we have registered the following copyrights, which we consider to be material to our business:

No.	Copyright	Registration No.	Date of Publication	Copyright Owner
1 . .	Synyi “Digital Intelligence Medical Brain” Healthcare Vertical Large Model Application Software V1.0 (森億“數智醫腦”醫療健康垂類大模型應用軟件V1.0)	2025SR1270735	July 16, 2025	Our Company

APPENDIX IV STATUTORY AND GENERAL INFORMATION

No.	Copyright	Registration No.	Date of Publication	Copyright Owner
2 . .	Synyi AI-Driven Intelligent Agent Collaboration Platform Software V1.0 (森億基於人工智能大模型驅動的智能體協同平台軟件V1.0)	2025SR1270726	July 16, 2025	Our Company
3 . .	Synyi Specialized Medical Intelligent Platform Software V1.0 (森億專科醫療智能平台軟件V1.0)	2025SR0525883	March 26, 2025	Our Company
4 . .	Synyi Specialized Disease Quality Control Platform Software V1.0 (森億專科專病質控平台軟件V1.0)	2025SR0525886	March 26, 2025	Our Company
5 . .	Synyi Unified Command and Dispatch Center Software V1.0 (森億統一指揮調度中心軟件V1.0)	2024SR1271221	August 29, 2024	Our Company
6 . .	Synyi AI Knowledge Middle Platform-Based Research Software V1.0 (森億基於智能化知識中台的科研平台軟件V1.0)	2023SR1461949	November 17, 2023	Our Company
7 . .	Synyi Generative AI Intelligent Editor Software V2.0 (森億生成式AI智能編輯器軟件V2.0)	2023SR1280577	October 23, 2023	Our Company
8 . .	Synyi Hospital Grade Review Auxiliary Management Platform Software V2.0 (森億醫院等級評審輔助管理平台軟件V2.0)	2023SR0606888	June 8, 2023	Our Company
9 . .	Synyi AI-Based Unified Early Warning Management Platform Software V1.0 (森億基於AI的統一預警管理平台軟件V1.0)	2023SR0602100	June 8, 2023	Our Company
10 . .	Synyi Intelligent Venous Thromboembolism (VTE) Information Management Software V1.0 (森億智能靜脈血栓栓塞症(VTE)信息管理軟件V1.0)	2023SR0575776	May 31, 2023	Our Company
11 . .	Synyi Intelligent Medical Management Platform Software V1.0 (森億智能醫務管理平台軟件V1.0)	2023SR0615194	June 9, 2023	Our Company
12 . .	Synyi Knowledge Middle Platform Natural Language Processing (NLP) Center Software V1.0 (森億知識中台自然語言處理(NLP)中心軟件V1.0)	2023SR0986543	August 30, 2023	Our Company
13 . .	Synyi Knowledge Middle Platform Rules Center Software V1.0 (森億知識中台規則中心軟件V1.0)	2023SR0812188	July 6, 2023	Our Company
14 . .	Synyi Knowledge Middle Platform Variables Center Software V1.0 (森億知識中台變量中心軟件V1.0)	2023SR1229151	October 13, 2023	Our Company
15 . .	Synyi Knowledge Middle Platform Forms Center Software V1.0 (森億知識中台表單中心軟件V1.0)	2023SR1613479	December 12, 2023	Our Company
16 . .	Synyi Comprehensive Medical Quality Intelligent Management Platform Software V1.0 (森億全面醫療質量智能管理平台軟件V1.0)	2023SR0556196	May 22, 2023	Our Company

APPENDIX IV STATUTORY AND GENERAL INFORMATION

No.	Copyright	Registration No.	Date of Publication	Copyright Owner
17.	Synyi Intelligent Medical Record Connotation Quality Control Software V1.0 (森億智能病歷內涵質控軟件V1.0)	2023SR0527285	May 9, 2023	Our Company
18.	Synyi Intelligent Full-Process Single Disease Quality Control Management Platform Software V1.0 (森億智能化全流程單病種質控管理平台軟件V1.0)	2021SR1730918	November 15, 2021	Our Company
19.	Synyi AI-Based Medical Terminology Automatic Standardization Engine Software V1.0 (森億基於人工智能的醫學術語自動標準化引擎軟件V1.0)	2021SR1555364	October 25, 2021	Our Company
20.	Synyi AI-Based Medical Variables Application Platform Software V1.0 (森億基於人工智能的醫學變量應用平台軟件V1.0)	2021SR1476494	October 9, 2021	Our Company
21.	Synyi AI-Based Main Index Automatic Calculation Engine Software V1.0 (森億基於人工智能的主索引自動計算引擎軟件V1.0)	2021SR1555365	October 25, 2021	Our Company
22.	Synyi Regional Medical Big Data Asset Management Software V1.0 (森億區域醫療大數據資產管理軟件V1.0)	2022SR0379608	March 23, 2022	Our Company
23.	Synyi Medical Regex Production Management Software V1.0 (森億醫學正則生產管理軟件V1.0)	2021SR1417085	September 23, 2021	Our Company
24.	Synyi Medical Data Automated ETL Software V1.0 (森億醫療數據自動化ETL軟件V1.0)	2021SR0811099	June 1, 2021	Our Company
25.	Synyi Maternal and Child Medicine Integration Acceleration Platform Software V2.4 (森億產醫融合加速平台軟件V2.4)	2021SR0882147	June 11, 2021	Our Company
26.	Synyi Data Analysis Indicator Unified Management Platform Software V1.0 (森億數據分析指標統一管理平台軟件V1.0)	2021SR1475933	October 9, 2021	Our Company
27.	Synyi Regional Medical Big Data Center Platform Software V1.0 (森億區域醫療大數據中心平台軟件V1.0)	2021SR1423243	September 24, 2021	Our Company
28.	Synyi Hospital-Wide Clinical Knowledge Base and Disease Intelligent Control Platform Software V1.0 (森億全院級臨床知識庫與疾病智能管控平台軟件V1.0)	2020SR1730749	December 3, 2020	Our Company
29.	Synyi Atrial Fibrillation Intelligent Auxiliary Management Software V1.0 (森億房顫智能輔助管理軟件V1.0)	2021SR0024349	January 6, 2021	Our Company
30.	Synyi Smart Hospital Operations Management Platform Software V1.0 (森億智慧醫院運營管理平台軟件V1.0)	2020SR1518565	October 23, 2020	Our Company

APPENDIX IV STATUTORY AND GENERAL INFORMATION

No.	Copyright	Registration No.	Date of Publication	Copyright Owner
31.	Synyi Clinical Decision Support System (CDSS) Knowledge Rules Engine Software V1.0 (森億臨床輔助決策支持CDSS知識規則引擎軟件V1.0)	2020SR0634603	June 16, 2020	Our Company
32.	Synyi Master Data and Medical Terminology Software V1.0 (森億主數據及醫學術語軟件V1.0)	2020SR0640136	June 1, 2021	Our Company
33.	Synyi Integrated Clinical Research Platform Software V3.0 (森億臨床科研一體化平台軟件V3.0)	2020SR0643410	June 17, 2020	Our Company
34.	Synyi Venous Thromboembolism (VTE) Prevention and Control Management Platform Software V2.0 (森億靜脈血栓栓塞症(VTE)防治管控平台軟件V2.0)	2020SR0643601	June 17, 2020	Our Company
35.	Synyi Third-Level Public Hospital Performance Evaluation Software V1.0 (森億三級公立醫院績效考核軟件V1.0)	2019SR1035725	October 12, 2019	Our Company
36.	Synyi Medical Knowledge Graph Software V1.0 (森億醫學知識圖譜軟件V1.0)	2019SR0974923	September 19, 2019	Our Company
37.	Synyi Intelligent Data NLP Model Software V1.0 (森億智能數據NLP模型軟件V1.0)	2019SR1036209	October 12, 2019	Our Company
38.	Synyi Disease Prediction Model Intelligent Construction Software V1.0 (森億疾病預測模型智能構建軟件V1.0)	2019SR1036268	October 12, 2019	Our Company
39.	Synyi Case Coding and Quality Control Platform Software V1.0 (森億病案智能編碼與質控平台軟件V1.0)	2019SR0176767	February 25, 2019	Our Company
40.	Synyi Intelligent Deep Venous Thrombosis (VTE) Control Platform Software V1.0 (森億智能深靜脈血栓(VTE)管控平台軟件V1.0)	2019SR0176772	February 25, 2019	Our Company
41.	Synyi Medical Big Data Platform Software V1.0 (森億醫療大數據平台軟件V1.0)	2019SR0666407	June 28, 2019	Our Company
42.	Synyi Medical Data Intelligent Extraction and Transformation Software V1.0 (森億醫療數據智能抽取轉換軟件V1.0)	2019SR0666214	June 28, 2019	Our Company
43.	Synyi AI-Based Data Governance Platform Software V1.0 (森億基於人工智能的數據治理平台軟件V1.0)	2019SR0176843	February 25, 2019	Our Company
44.	Synyi AI-Based Hospital Information Platform Software V1.0 (森億基於人工智能的醫院信息平台軟件V1.0)	2019SR0178130	February 25, 2019	Our Company
45.	Synyi Intelligent Clinical Decision Support Platform Software V1.0 (森億智能臨床決策支持平台軟件V1.0)	2019SR0178659	February 25, 2019	Our Company
46.	Synyi Integrated Clinical Research Platform Software V1.0 (森億臨床科研一體化平台軟件V1.0)	2017SR732573	December 26, 2017	Our Company

APPENDIX IV STATUTORY AND GENERAL INFORMATION

No.	Copyright	Registration No.	Date of Publication	Copyright Owner
47. .	Synyi Specialized Disease Database Platform Software V1.0 (森億專病數據庫平台軟件V1.0)	2019SR0118456	January 31, 2019	Our Company
48. .	Synyi Medical Knowledge Base Construction System V1.0 (森億醫學知識庫搭建系統V1.0)	2016SR380914	December 19, 2016	Our Company
49. .	Synyi Medical Text Intelligent Analysis Software V1.0 (森億醫學文本智能分析軟件V1.0)	2016SR403704	December 29, 2016	Our Company
50. .	Synyi Master Data and Medical Terminology System Software V1.0 (森億主數據及醫學術語系統軟件V1.0)	2017SR733840	December 26, 2017	Our Company

Domain Names

As of the Latest Practicable Date, we have registered the following domain names, which we consider to be material to our business:

No.	Registered Owner	Domain Name	Registration Date	Expiry Date
1. . .	Our Company	synyi.com	March 12, 2016	March 12, 2027
2. . .	Yilianwang	ylianw.com	June 13, 2016	June 13, 2027
3.. . .	Mukang	mu-kang.com	September 4, 2019	September 4, 2026

Save as disclosed above, as of the Latest Practicable Date, there was no other trade or service mark, patent, intellectual or industrial property right which was material in relation to our business.

FURTHER INFORMATION ABOUT OUR DIRECTORS AND SUBSTANTIAL SHAREHOLDERS

1. Disclosure of Interests

Save as disclosed in the section headed “Substantial Shareholders” and below, immediately following completion of the [REDACTED] (without taking into account the H Shares which may be allotted and issued pursuant to the exercise of the [REDACTED]), so far as our Directors are aware, none of our Directors and chief executive has any interest or short positions in our Shares, underlying Shares or debentures of our Company or any associated corporations (within the meaning of Part XV of the SFO) which will have to be notified to our Company and the [REDACTED] pursuant to [REDACTED] of Part XV of the SFO (including interests and short positions which they are taken or deemed to have under such provisions of the SFO), or which will be required, pursuant to [REDACTED] of the SFO, to be entered in the register referred to therein, or which will be required to be notified to our Company and the [REDACTED] pursuant to the Model Code for Securities Transactions by Directors of Listed Issuers contained in the Listing Rules.

APPENDIX IV STATUTORY AND GENERAL INFORMATION

Our Company

Name	Position	Nature of interest	Class and Number of Shares held	Approximate percentage of shareholding in the relevant class of Shares immediately upon completion of the [REDACTED] (assuming the [REDACTED] is not exercised) ⁽¹⁾	Approximate percentage of shareholding in the total issued share capital of our Company immediately upon completion of the [REDACTED] (assuming the [REDACTED] is not exercised) ⁽¹⁾
				(%)	(%)
Dr. Zhang ⁽²⁾	Chairperson of our Board, executive Director, founder and chief executive officer	Beneficial owner; Interests in controlled corporations; interest held jointly with another person	[REDACTED] H Shares	[REDACTED]	[REDACTED]
Dr. Ma ⁽²⁾	Executive Director, co-founder and general manager of East China region	Beneficial owner; interest held jointly with another person	[REDACTED] H Shares	[REDACTED]	[REDACTED]

Notes:

- (1) The calculation is based on the total number of [REDACTED] H Shares in issue upon completion of the [REDACTED] (assuming the [REDACTED] is not exercised).
- (2) For details of Dr. Zhang’s and Dr. Ma’s interests, see “Substantial Shareholders.”

2. Substantial Shareholders

For the information on the persons who will, immediately following the completion of the [REDACTED], have interests or short positions in our Shares or underlying Shares which would be required to be disclosed to our Company and the [REDACTED] under the provisions of [REDACTED] of Part XV of the SFO, see “Substantial Shareholders” in this document.

APPENDIX IV STATUTORY AND GENERAL INFORMATION

Save as set out below, our Directors are not aware of any other person (other than our Directors or chief executive) who will, immediately following completion of the [REDACTED], directly or indirectly, be interested in 10% or more of the nominal value of any class of share capital carrying rights to vote in all circumstances at general meetings of any member of our Group other than our Company.

<u>Our Subsidiary</u>	<u>Total Registered capital</u>	<u>Person with 10% or more interest</u>	<u>Approximate percentage of the interest in the subsidiary</u>
	(RMB)		
Yilianwang	31,714,286	Mr. CHENG Ren (程韜)	49%
Mukang	6,160,000	Shanghai Mukang Information Technology Co., Ltd. (上海 睦康企業管理中心(有限合 夥))	26.79%
		MA Junhua (馬俊華)	22.21%

3. Service Contracts

Each of our Directors [has] entered into a service contract with our Company. The principal particulars of these service contracts comprise (a) a term commencing on the date of the approval at the Company’s general meeting and ending on the expiration of the term of office of the prevailing session of the Board (with respect to Directors); and (b) termination provisions in accordance with their respective terms. Our Directors may be re-appointed subject to Shareholders’ approval.

Save as disclosed above, none of our Directors has or is proposed to have entered into any service contract with any member of our Group (excluding contracts expiring or determinable by any member of our Group within one year without payment of compensation other than statutory compensation).

4. Remuneration of Directors

Save as disclosed in the section headed “Directors and Senior Management” in this document and note 8 to the Accountants’ Report in Appendix I to this document, for the three financial years ended December 31, 2023, 2024 and 2025, none of our Directors received other remunerations of benefits in kind from us.

APPENDIX IV

STATUTORY AND GENERAL INFORMATION

5. Disclaimers

- (a) Save as disclosed in this section and the section headed “History, Development and Corporate Structure” in this document, none of our Directors and the parties listed in the paragraph headed “— Other Information — 5. Qualifications of Experts” in this Appendix is:
 - (i) interested in our promotion, or in any assets which have been, within two years immediately preceding the date of this document, acquired or disposed of by or leased to us, or are proposed to be acquired or disposed of by or leased to any member of our Company; or
 - (ii) materially interested in any contract or arrangement subsisting at the date of this document which is significant in relation to our business.
- (b) Save in connection with the [REDACTED] and the [REDACTED], none of the parties listed in the paragraph headed “— Other Information — 5. Qualification of Experts” in this Appendix:
 - (i) is interested legally or beneficially in any shares in any member of our Group; or
 - (ii) has any right (whether legally enforceable or not) to subscribe for or to nominate persons to subscribe for any securities in any member of our Group.
- (c) Save as disclosed in this section and the section headed “Directors and Senior Management” in this document, none of our Directors is a director or employee of a company that has an interest in the share capital of our Company which, once the H Shares are [REDACTED] on the [REDACTED], would have to be disclosed pursuant to Divisions 2 and 3 of Part XV of the SFO.
- (d) So far as is known to our Directors, none of our Directors or their respective close associates (as defined under the Listing Rules) or Shareholders who owns more than 5% of the issued Shares of our Company has any interests in the five largest customers or the five largest suppliers of our Group.

OTHER INFORMATION

1. Estate duty

Our Directors have been advised that no material liability for estate duty is likely to impose on our Company or any of our subsidiaries under the laws of the PRC.

APPENDIX IV

STATUTORY AND GENERAL INFORMATION

2. Litigation

As of the Latest Practicable Date, no member of our Group was involved in any litigation, arbitration or claim of material importance, and, so far as we are aware, no litigation, arbitration or claim of material importance is pending or threatened against any member of our Group, which would have a material adverse effect on our financial condition or results of operations, taken as a whole.

3. Joint Sponsors

The Joint Sponsors have made an application on behalf of our Company to the Hong Kong [REDACTED] for the approval of the [REDACTED] of, and permission to [REDACTED], our H Shares in [REDACTED] and to be [REDACTED] as mentioned in this document. All necessary arrangements have been made to enable the H Shares to be admitted into CCASS.

The Joint Sponsors satisfy the independence criteria applicable to sponsors set out in Rule 3A.07 of the Listing Rules. The Joint Sponsors will receive a fee of US\$450,000 (inclusive of tax), US\$250,000 (inclusive of tax) and HK\$1,000,000 (inclusive of tax) to act as a sponsor to our Company in connection with the [REDACTED].

4. Preliminary expenses

As of the Latest Practicable Date, our Company has not incurred material preliminary expenses.

5. Qualifications of Experts

The qualifications of the experts (as defined under the Listing Rules and the Companies (Winding Up and Miscellaneous Provisions) Ordinance) who have given opinions and/or advice in this document are as follows:

Name	Qualifications
China Securities (International) Corporate Finance Company Limited	A licensed corporation to conduct Type 1 (dealing in securities) and Type 6 (advising on corporate finance) regulated activities (as defined under SFO)
CCB International Capital Limited	A licensed corporation to conduct Type 1 (dealing in securities), Type 4 (advising on securities) and Type 6 (advising on corporate finance) regulated activities (as defined under SFO)

APPENDIX IV STATUTORY AND GENERAL INFORMATION

Name	Qualifications
BOCOM International (Asia) Limited	A licensed corporation under the SFO to carry on Type 1 (dealing in securities) and Type 6 (advising on corporate finance) regulated activities (as defined under SFO)
KPMG	Certified Public Accountants Public Interest Entity Auditor registered in accordance with the Accounting and Financial Reporting Council Ordinance
Jingtian & Gongcheng	Company’s PRC legal adviser
China Insights Industry Consultancy Limited	Independent industry consultant

6. Consents

Each of the experts as referred to in the paragraph headed “— Other Information — 5. Qualifications of Experts” in this Appendix has given and has not withdrawn its respective written consents to the issue of this document with the inclusion of certificates, letters, opinions or reports and the references to its name included herein in the form and context in which it respectively included.

7. Taxation of Holders of H Shares

(1) *Hong Kong*

The sale, purchase and transfer of H Shares are subject to Hong Kong stamp duty. The current rate charged on each of the purchaser and seller is 0.1% of the consideration or, if higher, the fair value of the H Shares being sold or transferred. For further details in relation to taxation, see “Regulatory Overview.”

(2) *Consultation with professional advisers*

Potential [REDACTED] in the [REDACTED] are urged to consult their professional tax advisers if they are in any doubt as to the taxation implications of [REDACTED] our H Shares (or exercising rights attached to them). None of our Company, our Directors, the Joint Sponsors, [REDACTED], or any other person or party involved in the [REDACTED] accept responsibility for any tax effects on, or liabilities of, any person, resulting from the [REDACTED] or the exercise of any rights in relation to our H Shares.

APPENDIX IV

STATUTORY AND GENERAL INFORMATION

8. No Material Adverse Change

Our Directors confirm that, as of the date of this document, there has been no material adverse change in the financial or trading position of our Company since December 31, 2025 (being the latest balance sheet date of our consolidated financial statements as set out in the Accountants’ Report).

9. Promoters

The promoters of our Company are all then 29 shareholders of our Company as of August 31, 2025 before our conversion into a joint stock company with limited liability. Save as disclosed in the section headed “History, Development and Corporate Structure” in this document, within the two years preceding the date of this document, no cash, securities or other benefit has been paid, allotted or given or is proposed to be paid, allotted or given to any promoter in connection with the [REDACTED] and the related transactions described in this document.

10. Restrictions on Repurchase

For details, see “Regulatory Overview” and Appendix III to this document.

11. Binding Effect

This document shall have the effect, if an application is made in pursuance of it, of rendering all persons concerned bound by all of the provisions (other than the penal provisions) of [REDACTED] of the Companies (Winding Up and Miscellaneous Provisions) Ordinance so far as applicable.

12. Bilingual Document

The English and Chinese language versions of this document are being published separately, in reliance upon the exemption provided under [REDACTED] of the Companies (Exemption of Companies and Prospectuses from Compliance with Provisions) Notice (Chapter 32L of the Laws of Hong Kong).

13. Miscellaneous

Save as otherwise disclosed in this document:

- (a) within the two years preceding the date of this document, (i) our Company has not issued nor agreed to issue any share or loan capital fully or partly paid either for cash or for a consideration other than cash; and (ii) no commission, discount, brokerage or other special term has been granted in connection with the issue or sale of any shares of our Company;

APPENDIX IV

STATUTORY AND GENERAL INFORMATION

- (b) no Share or loan capital of our Company, if any, is under option or is agreed conditionally or unconditionally to be put under option;
- (c) our Company has not issued nor agreed to issue any founder shares, management shares or deferred shares;
- (d) our Company has no outstanding convertible debt securities or debentures;
- (e) there is no arrangement under which future dividends are waived or agreed to be waived;
- (f) there has been no interruption in our business which may have or have had a significant effect on the financial position in the last 12 months;
- (g) our Company is not presently listed on any stock exchange or traded on any trading system; and
- (h) our Company is a joint stock limited company and is subject to the PRC Company Law.